The drug approval process for new products authorized in Canada, and elsewhere, essentially involves a comprehensive analysis of nonclinical and clinical studies. However, the management of adverse effects associated with these new health products does not end on granting market authorization. Rather, these surveillance activities continue throughout the entire drug's ()and this is made possible essentially through the passive and active surveillance of adverse drug reactions in the postmarket setting.